Aller au contenu principal
Profil bibliographique

Cathy Stevens

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

5Publications signalées
566Citations signalées
0Affiliations récentes

Les domaines associés

Neuropeptides and Animal PhysiologyNeurotransmitter Receptor Influence on BehaviorChronic Obstructive Pulmonary Disease (COPD) ResearchRespiratory Support and MechanismsDiabetes Treatment and Management

Les publications récentes

2010 article OpenAlex

Trendelenburg chest optimization prolongs spontaneous breathing trials in ventilator-dependent patients with low cervical spinal cord injury

Charles J. Gutierrez, Cathy Stevens, John L. Merritt, Cecille Pope et autres

Chest optimization, an evidence-based protocol-guided multimodal chest physiotherapy consisting of body positioning, sputum mobilization, bronchodilation, and lung hyperinflation, may be routinely administered to ventilator-dependent patients with low cervical spinal cord injury (CSCI) for improving pulmonary functional outcomes that facilitate weaning from mechanical …

us (code pays fourni par la source)

15 citations The Journal of Rehabilitation Research and Development
2007 article OpenAlex

Efficacy and Safety of Intranasal Peptide YY3–36 for Weight Reduction in Obese Adults

Ira Gantz, Ngozi Erondu, Madhuja Mallick, Bret J. Musser et autres

CONTEXT: The gastrointestinal peptide hormone, peptide YY(3-36) (PYY(3-36)), is implicated to be a postprandial satiety factor. OBJECTIVE: The aim of this study is to assess the safety, tolerability, and efficacy of intranasal PYY(3-36) to induce weight loss in obese patients. DESIGN: The …

us (code pays fourni par la source)

164 citations The Journal of Clinical Endocrinology & Metabolism
2006 article OpenAlex

Pharmacokinetics and Pharmacodynamic Effects of the Oral DPP‐4 Inhibitor Sitagliptin in Middle‐Aged Obese Subjects

Gary A. Herman, Arthur J. Bergman, Fang Liu, Cathy Stevens et autres

Sitagliptin (MK-0431) is an oral, potent, and selective dipeptidyl peptidase-IV (DPP-4) inhibitor developed for the treatment of type 2 diabetes. This multicenter, randomized, double-blind, placebo-controlled study examined the pharmacokinetic and pharmacodynamic effects of sitagliptin in obese subjects. Middle-aged (45-63 years), nondiabetic, obese …

us (code pays fourni par la source)

187 citations The Journal of Clinical Pharmacology

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.